1. India’s Dr Reddy’s sees no impact from pricing regulator notice

India’s Dr Reddy’s sees no impact from pricing regulator notice

Dr Reddy's Laboratories Ltd , India's second-largest drugmaker by sales, said it expects no impact from a recent government notice that said the company is selling a high blood pressure drug that lacks the pricing regulator's approval.

By: | Mumbai | Published: May 19, 2017 7:13 PM
Dr Reddy's Laboratories Ltd, India, pricing regulator notice, NPPA, high blood pressure drug India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), issued a show-cause notice to dozens of Indian and foreign drugmakers, who according to them, were selling medicines without NPPA approval on pricing.

Dr Reddy’s Laboratories Ltd , India’s second-largest drugmaker by sales, said it expects no impact from a recent government notice that said the company is selling a high blood pressure drug that lacks the pricing regulator’s approval. India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), issued a show-cause notice to dozens of Indian and foreign drugmakers, who according to them, were selling medicines without NPPA approval on pricing. Calling it a violation of the country’s drugs law, the agency has sought an explanation from these companies by June 15.

You may also like to watch:

Dr Reddy’s Telsartan Trio Active, which is used to treat high blood pressure and diabetic kidney disease, was included in the list. “Dr Reddy’s is in compliance with the NPPA’s norms,” a company spokeswoman told Reuters in an emailed statement on Friday. “There is a discrepancy in data compilation by NPPA and we will communicate it to them appropriately,” she added. The company did not immediately respond to a request for further clarifications.

  1. No Comments.

Go to Top